Roth MKM Sticks to Their Buy Rating for IMAX (IMAX)
Don't Miss TipRanks' Half-Year Sale
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
According to TipRanks, Handler is a 5-star analyst with an average return of 13.7% and a 65.38% success rate. Handler covers the Communication Services sector, focusing on stocks such as Cinemark Holdings, Electronic Arts, and IMAX.
IMAX has an analyst consensus of Strong Buy, with a price target consensus of $32.56, implying a 21.04% upside from current levels. In a report released on June 30, Benchmark Co. also reiterated a Buy rating on the stock with a $30.00 price target.
Based on IMAX's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $86.67 million and a net profit of $2.33 million. In comparison, last year the company earned a revenue of $79.12 million and had a net profit of $3.27 million
Based on the recent corporate insider activity of 28 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of IMAX in relation to earlier this year. Most recently, in May 2025, Richard Gelfond, the CEO of IMAX sold 100,000.00 shares for a total of $2,711,000.00.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
9 hours ago
- Business Wire
HOYTS Cinemas and IMAX Relaunch Partnership with Up to Five New IMAX With Laser Locations Across Australia
SYDNEY & NEW YORK--(BUSINESS WIRE)--IMAX Corporation (NYSE: IMAX) and HOYTS Cinemas, one of Australia's leading cinema chains, today announced a new agreement for up to five state-of-the-art IMAX® with Laser systems throughout Australia. The deal reignites the partnership between the two companies, which have not operated an IMAX location together since 2019. The first new IMAX location is slated to open in Melbourne later in 2025, in advance of the release of 'Avatar: Fire and Ash'. Up to an additional four locations will be identified for future expansion. 'As the pioneer of IMAX screens in multiplex cinema in Australia, HOYTS is delighted to partner with IMAX again. Our foundation site at Melbourne Central will be open for 'Avatar: Fire and Ash,' with more sites to be announced shortly,' said Damien Keogh, CEO and President of HOYTS Group. 'Every one of our cinemas has touch points that elevate them from a usual experience: from the quality of our recliners, through to state-of-the-art technical enhancements. The opportunity to see things on IMAX is really going to enhance HOYTS' reputation as the premier destination for film experiences.' 'Australia continues to be a priority for IMAX, and this agreement with HOYTS Cinemas to expand and diversify our footprint is just the latest sign of our strong momentum in this thriving moviegoing market,' said Rich Gelfond, CEO of IMAX. 'HOYTS is an exceptional, well-established exhibitor in Australia and New Zealand, and we're looking forward to getting back in business with the company to further satisfy surging demand for the IMAX Experience.' IMAX has seen unprecedented growth in Australia, driven by strong box office performance and exceptional moviegoer demand. The company's footprint in Australia has grown from just one location in 2022 to four currently in operation and another ten set to open in the next several years. Australia currently ranks as the tenth market overall for IMAX box office — a stellar result from just four locations in the country and ranking behind powerhouse IMAX markets like the U.S., China, Japan and the UK. Last year, IMAX notched its highest grossing year since 2015 in Australia, and the country was the top market overall by per-screen-average (PSA) for IMAX, with an average of nearly $4.5 million per screen. The deal comes as IMAX continues a hot streak of Filmed for IMAX titles – in Australia, IMAX delivered nearly 6% of last weekend's debut of 'Superman,' despite only having four locations in the country. Earlier this summer, 'Mission: Impossible – The Final Reckoning' was among the top opening weekends ever for IMAX in Australia, delivering over $400K in box office. Overall, IMAX indexing in Australia has grown dramatically, going from 2.6% of the overall box office in 2024 to 4.4% in 2025 to date, with several Filmed for IMAX titles to go including next week's debut of Disney/Marvel's 'The Fantastic Four: First Steps.' The new HOYTS IMAX locations will be equipped with IMAX with Laser, IMAX's most advanced cinema experience. Developed from the ground up for maximum immersion, IMAX with Laser delivers crystal-clear 4K images, precision audio, and state-of-the-art projection technology, setting a new standard for moviegoing. The system features a groundbreaking optical engine, custom-designed lenses, and proprietary IMAX technology that delivers brighter images, deeper contrast, and the widest range of colors exclusively to IMAX screens. About HOYTS Since opening the doors of its first cinema in 1909, HOYTS has gone on to become one of the world's leading entertainment companies, with more than 500 screens and over 60,000 seats across the network. Today, HOYTS is the largest single-brand movie exhibitor in Australia and New Zealand. About IMAX Corporation IMAX, an innovator in entertainment technology, combines proprietary software, architecture, and equipment to create experiences that take you beyond the edge of your seat to a world you've never imagined. Top filmmakers and studios are utilizing IMAX systems to connect with audiences in extraordinary ways, making IMAX's network among the most important and successful theatrical distribution platforms for major event films around the globe. IMAX is headquartered in New York, Toronto, and Los Angeles, with additional offices in London, Dublin, Tokyo, and Shanghai. As of March 31, 2025, there were 1,810 IMAX systems (1,738 commercial multiplexes, 11 commercial destinations, 61 institutional) operating in 89 countries and territories. Shares of IMAX China Holding, Inc., a subsidiary of IMAX Corporation, trade on the Hong Kong Stock Exchange under the stock code '1970'. IMAX ®, IMAX ® 3D, Experience It In IMAX ®, The IMAX Experience ®, DMR ®, Filmed For IMAX ®, IMAX LIVE™, and IMAX Enhanced ® are trademarks and trade names of IMAX Corporation or its subsidiaries that are registered or otherwise protected under laws of various jurisdictions. For more information, visit You may also connect with IMAX on Instagram ( Facebook ( LinkedIn ( X ( and YouTube (
Yahoo
11 hours ago
- Yahoo
These 2 Momentum Stocks Got a Bullish Nod — Here's Why They Could Reach New Highs
Buying into rising stocks is a natural impulse – and it's a viable investing strategy. Momentum investing, as it's called, is the art of finding and following the market's upward trends. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Of course, every investing style has its boosters and its bummers, and both sides usually have strong arguments in their favor. The key to success is finding balance, and remembering that while past performance won't guarantee a future return, it can still provide useful indications of where a stock is heading. With that in mind, let's dive into a pair of momentum stocks that are currently catching investors' attention. Using the TipRanks database, we've zeroed in on two names that have not only gained steam lately, but have also received bullish endorsements from at least one Street analyst. Let's take a look. BridgeBio Pharma (BBIO) The first momentum stock on our list today is BridgeBio, a biopharmaceutical company with a focus on genetic diseases that are both rare and serious. More specifically, BridgeBio has chosen disease targets with what it describes as 'clear genetic drivers'; that is, it is developing drug candidates to treat diseases that are genetically linked to single mutations. BridgeBio has chosen a rich field in which to work, as it can choose from more than 10,000 genetic diseases that meet its target criteria – and they impact tens of millions of patients globally. More importantly, this group of diseases has relatively few FDA-approved medications, giving BridgeBio plenty of openings. BridgeBio bases its development work on its proprietary drug development platform, looking for novel genetic diseases to target and then creating new medicines to address symptoms and improve patient outcomes. The company follows this development stage by moving a drug candidate from a successful clinical trial series and into the regulatory process, with commercialization being the final goal. BridgeBio reached that goal late last year. This past November, the company received FDA approval of its drug acoramidis for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM), a disease that affects the heart muscle. Treatment with acoramidis was shown in clinical trials to reduce death and hospitalization from the disease, with statistically significant improvements in patients under treatment. BridgeBio is marketing the new drug under the brand name Attruby, and 1Q25 was the company's first full quarter of commercialization efforts. The company is still investigating acoramidis in the clinical trial program, where it is the subject of the Phase 3 ACT-EARLY study, testing whether the drug is useful in preventing asymptomatic patients who carry the pathogenic TTR variant from developing the active disease. Turning to the company's financial side, we find that BridgeBio's 1Q25 earnings release showed $116.6 million in total revenues, of which $36.7 million was net product revenue derived from sales of Attruby in the US following the drug's commercial launch. The balance of the company's revenue came from license and services income. Compared to the prior-year quarter, this segment of the revenue was down by $131.2 million, leading to the total revenue year-over-year decline of 45%, although the total haul actually beat Street expectations by $58 million, aided by Atturby's better-than-expected debut. BridgeBio ran a net loss in 1Q25, of 88 cents per share, yet this was 5 cents per share better than had been expected. Investors have liked the story here and the stock shows a strong gain for the year-to-date, up ~74%. BridgeBio has caught the attention of Oppenheimer analyst Trevor Allred, who is taking a more bullish stance on the shares in light of Attruby's successful commercialization. Allred writes, 'We've been wrong on BBIO since our initiation—Bridgebio's team has executed Attruby's launch superbly, and shares have been supported by commercial outperformance and a look-ahead to clinical catalysts at YE. Our trepidation around 2029 generic entry has not mattered for 2025 stock performance. We expect share outperformance to continue as 2025 Attruby sales clear consensus estimates, and we expect commercial success to be compounded by positive clinical results from ADH1 and LGMD2i clinical trials around YE. Our concerns regarding long-term revenue durability remain, but BBIO has time to demonstrate real-world datasets demonstrating benefit over tafamidis should generics become available in 2029.' Allred follows these comments with an upgrade from Perform (i.e., Neutral) to Outperform (i.e., Buy) rating for BBIO, and a $60 price target that implies a one-year upside potential of 26%. (To watch Allred's track record, click here) Overall, this stock has earned a Strong Buy consensus rating from the Street, based on 18 recent reviews that have a lopsided breakdown of 17 Buys to 1 Hold. The shares are priced at $47.69, and their $62.75 average target price suggests that the stock will gain 31.5% by this time next year. (See BBIO stock forecast) So-Young International (SY) Next up on our list of momentum stocks is So-Young, a Chinese company. The firm that operates a social media platform, linked to the medical aesthetics industry, and connecting the varied consumers, professionals, and medical service providers in the aesthetics sector. The platform makes available reliable and trustworthy information on a carefully vetted and curated network of medical aesthetic providers. The service platform focuses on content distribution in China, making use of major social media networks and other targeted media platforms. Social media and medical aesthetics are both growth industries, and So-Young is building a brand image based on user trust, an extensive reach, and valuable data insights. So-Young's user base can trade information on clinics, the latest treatment trends in aesthetics, and the quality of treatment, all permitting better patient decisions – and based on the trust engendered by sharing personal experiences. The company is working to expand its network, to add additional medical fields such as dentistry, dermatology, ophthalmology, and basic physical exams. The service is focused on China, and the company is based in Beijing. In its financial release for 1Q25, So-Young reported important gains in the number of active users on its network and the number of verified paid visits. The active users – defined as those who had visited an aesthetic clinic at least once in the previous 12 months – totaled more than 75,500, a massive gain from the 8,000 reported in the prior-year period. The gain in verified paid visits was similar, with 45,500 in 1Q25 compared to 4,600 in 1Q24. The company reported Q1 revenue at the high end of its previously published guidance range, with a top line of RMB297.3 million (approximately US$41 million) compared with RMB318.3 million in the first quarter of 2024, a figure that beat Street expectations by $0.8 million. The shares have been on a huge runup, up 411% this year, the bulk of the gains generated over the past month and this Chinese momentum stock has come to the attention of Citi analyst Nelson Cheung, who is impressed by the company's recent growth. Cheung says of So-Young and its prospects, 'Since launch in Nov 2024, SoYoung Clinic has quickly expanded with 31 centers in major cities (Beijing, Shanghai, Shenzhen) by end-Jun, verifying SY's strength in 1) differentiating brand position for quality standardized service and value-for-money mindshare for mass public; 2) increasing pricing power over procurement as it scales up; 3) effective online private domain cross-selling for accurate targeting and site selection; 4) proven execution for profitable store management with ~80% aesthetic centers generating +ve op cash flow in 1Q. We see meaningful catalysts to drive stock price further if: 1) improving monthly sales for flagship stores in Jun (e.g. Beijing Baoli); 2) potential exploration of full managed franchising model by end 2025; 3) solid exclusive product pipeline until 2027E.' (To watch Cheung's track record, click here) Looking forward, Cheung rates this stock as a Buy, with a $5.50 price target that suggests a one-year gain for the stock of 30%. Cheung's is the only analyst review on file for this stock, which is currently trading for $4.24. (See SY stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment. Disclaimer & DisclosureReport an Issue Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
12 hours ago
- Business Insider
AMD Stock Soars as Trump Lifts China AI Chip Ban
Advanced Micro Devices (AMD) stock rallied on Tuesday after President Donald Trump lifted his ban on artificial intelligence (AI) chip sales to China. The latest reports claim that AMD has gained permission to sell its MI308 chips to Chinese customers, despite concerns that this would benefit the country's military and AI sectors. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Investors will note that the Commerce Department hasn't yet confirmed the lifting of the ban on sales of AI chips to China. However, AMD rival Nvidia (NVDA) has confirmed its ability to sell H20 chips to customers in the country. President Trump's reversal of the AI chip ban is likely tied to ongoing pressure from the tech industry. Nvidia CEO Jensen Huang has been among the figures who have publicly called on the U.S. President to relax restrictions around AI chip sales to China. It appears President Trump has taken that advice. AMD Stock Movement Today AMD stock was up 6.64% on Tuesday morning, extending a 29.15% rally year-to-date. However, the shares have still fallen 17.53% over the past 12 months. Today's news comes with strong trading of AMD stock, with some 44 million shares having changed hands. This is closing in on the semiconductor company's three-month daily average trading volume of roughly 48.49 million shares. In related news, AMD stock received updated coverage from five-star Bernstein analyst Stacy Rasgon today. Rasgon reiterated a Hold rating and $95 price target, suggesting a 39.3% downside for the shares. Is AMD Stock a Buy, Sell, or Hold? Turning to Wall Street, the analysts' consensus rating for AMD is Moderate Buy, based on 25 Buy and 10 Hold ratings over the past three months. With that comes an average AMD stock price target of $135.97, representing a potential 13.37% downside for the shares.
